Kang Chen Pharmaceuticals (603590.SH) announced on October 29th that its revenue for the first three quarters of 2024 was approximately 0.646 billion yuan, a decrease of 10.24% year-on-year; net income attributable to shareholders of the listed company was approximately 0.113 billion yuan, a decrease of 23.99% year-on-year; and the basic earnings per share was 0.7189 yuan.
康辰药业(603590.SH)：前三季度净利润约1.13亿元，同比减少23.99%
Beijing Konruns Pharmaceutical (603590.SH): The net income in the first three quarters is approximately 0.113 billion yuan, a decrease of 23.99% year-on-year.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated